To better understand the potential immune value of EPHX2, we assessed the immune score of cancer patients from the TCGA cohort using the ESTIMATE and CIBERSORT algorithms and discovered that EPHX2 expression was strongly correlated with Th17 cells, Th1 cells, NK CD56dim cells, NK CD56bright cells, neutrophils, macrophages, T cells CD4 memory activated, mast cells resting, monocytes, and T cells regulatory Tregs in most tumors. Here, CD4 is linked to cancer.